|
|
Blood, 15 November 2008, Vol. 112, No. 10, pp. 4158-4169.
Prepublished online as a Blood First Edition Paper on August 7, 2008; DOI 10.1182/blood-2008-02-140814.
Previous Article | Next Article 
Submitted February 22, 2008
Accepted July 20, 2008
Wiskott-Aldrich Syndrome protein deficiency in B cells results in impaired peripheral homeostasis
Almut Meyer-Bahlburg, Shirly Becker-Herman, Stephanie Humblet-Baron, Socheath Khim, Michele Weber, Gerben Bouma, Adrian J Thrasher, Facundo D Batista, and David J Rawlings*
Department of Pediatrics, Seattle Children's Hospital Research Institute, Seattle, WA, United States
Center for Cellular and Molecular Therapy, GIGA-R, University of Liege, Liege, Belgium
Lymphocyte Interaction Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
Center for Immunodeficiency, University College London and Great Ormond Street Hospital for Children, London, United Kingdom
Department of Immunolgy, University of Washington School of Medicine, Seattle, WA, United States
* Corresponding author; email: drawling{at}u.washington.edu.
In order to more precisely identify the B cell phenotype in Wiskott-Aldrich Syndrome (WAS), we utilized three distinct murine in vivo models to define the cell intrinsic requirements for Wiskott-Aldrich Syndrome protein (WASp) in central vs. peripheral B cell development. While WASp is dispensable for early bone marrow B cell development, WASp deficiency results in a marked reduction in each of the major mature peripheral B cell subsets exerting the greatest impact on marginal zone (MZ) and B1a B cells. Using in vivo BrdU labeling and in vitro functional assays, we show that these deficits reflect altered peripheral homeostasis, partially due to an impairment in integrin function, rather than a developmental defect. Consistent with these observations we also show that: WASp expression levels increase with cell maturity peaking in those subsets exhibiting the greatest sensitivity to WASp deficiency; WASp+ murine B cells exhibit a marked selective advantage beginning at the late transitional B cell stage; and, finally, that a similar in vivo selective advantage is manifest by mature WASp+ human B cells. Together, our data provide a better understanding of the clinical phenotype of WAS and suggest that gene therapy might be a useful approach to rescue altered B cell homeostasis in this disease.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
WASp stings mature lymphocytes
- Eva Severinson
Blood 2008 112: 3921-3922.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
M. Bosticardo, F. Marangoni, A. Aiuti, A. Villa, and M. Grazia Roncarolo
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome
Blood,
June 18, 2009;
113(25):
6288 - 6295.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Astrakhan, H. D. Ochs, and D. J. Rawlings
Wiskott-Aldrich Syndrome Protein Is Required for Homeostasis and Function of Invariant NKT Cells
J. Immunol.,
June 15, 2009;
182(12):
7370 - 7380.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|